Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Servier Links Up With Celladon For Potential Diabetes Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Servier inks its second deal in less than two weeks, this time for potential diabetes candidates. While both deals are early, they mark the French biotech’s foray into two hot fields of research.

You may also be interested in...

Deals Of The Week: Novartis Places Bid To Dominate In Cancer

Novartis beefs up its immunotherapy pipeline, while French biotech Servier makes a play to get in the CART game. Yet, the deal on everybody’s lips is Actavis’ acquisition of Forest. Plus news on Gilead and Pfizer.

Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies

The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts